Therapeutic antitumor efficacy of tumor-derived autophagosome (DRibble) vaccine on head and neck cancer

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 1921-1930

  Su, Hang ^a   Luo, Qiong ^b   Xie, Hao ^c   Huang, Xiaofeng ^a   Ni, Yanhong ^a   Mou, Yongbin ^a   Hu, Qingang ^a,d  

^a Center Laboratory of Stomatology Stomatological Hospital Affiliated Medical School   (China)

^b NANJING UNIVERSITY   (China)

^c SOUTHEAST UNIVERSITY   (China)

^d UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Antitumor immunity; Autophagy; Dendritic cells; Head and neck cancer; Nanoparticles

Indexed keywords

CD40 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NANOPARTICLE; PROTEASOME; TUMOR DERIVED AUTOPHAGOSOME VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; B LYMPHOCYTE; BONE MARROW; CANCER CELL LINE; CANCER INHIBITION; COCULTURE; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CANCER; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; LYSOSOME; MEMBRANE STRUCTURE; MONOCYTE; MOUSE; NONHUMAN; PARTICLE SIZE; SURVIVAL RATE; T LYMPHOCYTE; TUMOR CELL; UPREGULATION; ANIMAL; AUTOPHAGY; CELL CULTURE; HEAD AND NECK NEOPLASMS; IMMUNOLOGY;

ANIMALIA; MUS;

ANIMALS; AUTOPHAGY; CANCER VACCINES; CELLS, CULTURED; DENDRITIC CELLS; HEAD AND NECK NEOPLASMS; MICE;

EID: 84928139637     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S74204     Document Type: Article

References (37)

1. Bevan MJ. Cross-priming. Nat Immunol. 2006;7:363–365.
2. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med. 1976;143:1283–1288.
3. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol. 2001;19:47–64.
4. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 1994;264:961–965.
5. Burgdorf S, Kurts C. Endocytosis mechanisms and the cell biology of antigen presentation. Curr Opin Immunol. 2008;20:89–95.
6. Lin NY, Beyer C, Giessl A, et al. Autophagy regulates TNFα-mediated joint destruction in experimental arthritis. Ann Rheum Dis. 2013;72:761–768.
7. Abeliovich H, Dunn WA Jr, Kim J, Klionsky DJ. Dissection of autophagosome biogenesis into distinct nucleation and expansion steps. J Cell Biol. 2000;151:1025–1034.
8. Dikic I, Johansen T, Kirkin V. Selective autophagy in cancer development and therapy. Cancer Res. 2010;70:3431–3434.
9. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer. 2007;7:961–967.
10. Levy JM, Thorburn A. Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacol Ther. 2011;131:130–141.
11. Amaravadi RK, Lippincott-Schwartz J, Yin XM, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011;17:654–666.
12. Liu EY, Ryan KM. Autophagy and cancer – issues we need to digest. J Cell Sci. 2012;125:2349–2358.
13. Schmid D, Munz C. Innate and adaptive immunity through autophagy. Immunity. 2007;27:11–21.
14. Heath RJ, Xavier RJ., Autophagy, immunity and human disease. Curr Opin Gastroenterol. 2009;25:512–520.
15. Li Y, Wang LX, Yang G, Hao F, Urba WJ, Hu HM. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res. 2008;68:6889–6895.
16. Li Y, Wang LX, Pang P, et al. Cross-presentation of tumor associated antigens through tumor-derived autophagosomes. Autophagy. 2009;5:576–577.
17. English L, Chemali M, Duron J, et al. Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection. Nat Immunol. 2009;10:480–487.
18. Jagannath C, Lindsey DR, Dhandayuthapani S, Xu Y, Hunter RL Jr, Eissa NT. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat Med. 2009;15:267–276.
19. Twitty CG, Jensen SM, Hu HM, Fox BA. Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism. Clin Cancer Res. 2011;17:6467–6481.
20. Mou Y, Chen B, Zhang Y, et al. Influence of synthetic superparamagnetic iron oxide on dendritic cells. Int J Nanomedicine. 2011;6:1779–1786.
21. Li Y, Wang LX, Pang P, et al. Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res. 2011;17:7047–7057.
22. Klionsky DJ, Cuervo AM, Seglen PO. Methods for monitoring autophagy from yeast to human. Autophagy. 2007;3:181–206.
23. Duray A, Demoulin S, Hubert P, Delvenne P, Saussez S. Immune suppression in head and neck cancers: a review. Clin Dev Immunol. 2010;2010:701657.
24. Psyrri A, Rampias T, Vermorken JB. The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck. Ann Oncol. 2014;25:2101–2115.
25. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
26. Grégoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v184–v186.
27. Freiser ME, Serafini P, Weed DT. The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities. Immunol Res. 2013;57:52–69.
28. Mittendorf EA, Peoples GE, Singletary SE. Breast cancer vaccines: promise for the future or pipe dream? Cancer. 2007;110:1677–1686.
29. Corundolo V, Hermans IF, Salio M. Dendritic cells: a journey from laboratory to clinic. Nat Immunol. 2004;5:7–10.
30. Strome SE, Voss S, Wilcox R, et al. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res. 2002;62:1884–1889.
31. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12:265–277.
32. Gottfried E, Kreutz M, Mackensen A. Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Revs. 2008;19:65–77.
33. Wang ZY, Shi PH, Huang XF, et al. Peripheral blood dendritic cells and vascular endothelial growth factor in oral squamous cell carcinoma: correlation analysis and in vitro study. Int J Oral Maxillofac Surg. 2010;39:713–720.
34. Yewdell JW, Nicchitta CV. The DRiP hypothesis decennial: support, controversy, refinement and extension. Trends Immunol. 2006;27:368–373.
35. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy. 2007;3:542–545.
36. Pellegrini P, Strambi A, Zipoli C, et al. Acidic extracellular pH neutralizes the autophagy-inhibiting activity of chloroquine: implications for cancer therapies. Autophagy. 2014;10:562–571.
37. Lesterhuis WJ, Aarntzen E, De Vries IJ, et al. Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol. 2008;66:118–134.